Skip to main content
Premium Trial:

Request an Annual Quote

Japanese Drug Maker to Acquire Proteomics Shop ActivX for $21M

NEW YORK, Dec. 3 (GenomeWeb News) - Kyorin Pharmaceutical of Tokyo will buy proteomics company ActivX Biosciences for $21 million, the company said yesterday.

 

Kyorin will create a US subsidiary and merge it with ActivX, which will then become a wholly owned subsidiary of Kyorin. An acquisition date was not disclosed.

 

Kyroin and ActivX, of La Jolla, Calif., have collaborated since 2002 in a Type II diabetes discovery program, and in January expanded their activities to include metabolic disorders. ActivX also has collaborations with Pfizer, Gilead, and an undisclosed additional pharma partner.

 

ActivX uses a core proteomics technology, licensed from Scripps, that consists of fluorescent chemical affinity probes that bind to the active sites of a specific class of proteins.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.